新型冠状病毒 2019、微血栓和血小板激活因子。
Coronavirus 2019, Microthromboses, and Platelet Activating Factor.
机构信息
Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, USA; School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA; Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA.
Laboratory of Biology, Biochemistry and Microbiology, Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.
出版信息
Clin Ther. 2020 Oct;42(10):1850-1852. doi: 10.1016/j.clinthera.2020.08.006. Epub 2020 Aug 17.
Recent articles have reported elevated markers of coagulation, endothelial injury, and microthromboses in lungs from deceased patients with coronavirus 2019 (COVID-19). Platelets are critical in the formation of thrombi, and their most potent trigger is platelet activating factor (PAF). PAF is produced by cells involved in host defense, and its biological actions bear similarities with COVID-19 disease manifestations, including pulmonary microthromboses and inflammation, possibly via activation of mast cells. The histamine receptor antagonist rupatadine was developed to have anti-PAF activity and inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis.
最近的文章报道了在 2019 年冠状病毒病（COVID-19）死亡患者的肺部中存在凝血、内皮损伤和微血栓形成的标志物升高。血小板在血栓形成中至关重要，其最有效的触发因素是血小板激活因子（PAF）。PAF 由参与宿主防御的细胞产生，其生物学作用与 COVID-19 疾病表现相似，包括肺微血栓形成和炎症，可能通过激活肥大细胞。组胺受体拮抗剂 rupatadine 的开发具有抗 PAF 活性，并抑制人肥大细胞对 PAF 的激活。rupatadine 可被重新用于 COVID-19 的预防。
Zotero 插件